Impact of carrier particle surface properties on drug nanoparticle attachmentShow others and affiliations
2024 (English)In: International Journal of Pharmaceutics, ISSN 0378-5173, E-ISSN 1873-3476, Vol. 651, article id 123743Article in journal (Refereed) Published
Abstract [en]
Hypothesis: The stabilization and isolation to dryness of drug nanoparticles has always been a challenge for nano-medicine production. In the past, the use of montmorillonite (MMT) clay carrier particles to adsorb drug nanoparticles and maintain their high surface area to volume ratio after isolation to dryness has proven to be effective. We hypothesise that the distribution of hydrophilic and hydrophobic patches on the clay's surface as well as its porosity/roughness, hinder the agglomeration of the drug nanoparticles to the extent that they retain their high surface area to volume ratio and display fast dissolution profiles. Experiments: In this work, the distribution of hydrophobicity and hydrophilicity, and the porosity/roughness, of the surface of selected silica carrier particles were varied and the impact of these variations on drug nanoparticle attachment to the carrier particle and subsequent dissolution profiles was studied. Findings: The fastest dissolution profiles at the highest drug nanoparticle loadings were obtained with a periodic mesoporous organosilane carrier particle which had a homogeneous distribution of hydrophobic and hydrophilic surface properties. Carrier particles with rough/porous surfaces and a combination of hydrophobic and hydrophilic patches resulted in nanocomposite powders with faster dissolution behaviour than carrier particles with predominantly either a hydrophobic or hydrophilic surface, or with non-porous/smoother surfaces.
Place, publisher, year, edition, pages
Elsevier BV , 2024. Vol. 651, article id 123743
Keywords [en]
Carrier particles, Dissolution rate, Drug nanoparticles, Liquid antisolvent precipitation, Mesoporous silicates, Solubility
National Category
Polymer Chemistry Materials Chemistry Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:kth:diva-342625DOI: 10.1016/j.ijpharm.2023.123743ISI: 001154480900001PubMedID: 38151103Scopus ID: 2-s2.0-85182414173OAI: oai:DiVA.org:kth-342625DiVA, id: diva2:1831219
Note
QC 20240125
2024-01-252024-01-252024-06-19Bibliographically approved